Its sequencing devices are among the most widely distributed in global hospitals and laboratories of all stripes, and its ongoing years-long efforts to develop new technologies place it at the cutting edge of the field, with few notable competitors anywhere in sight. Illumina is currently facing some serious legal trouble in the E.U. to the point where it constitutes a red flag for its near-term performance. To prepare for the possible fine, Illumina is setting aside $453 million.
Zacks.com users have recently been watching Illumina (ILMN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Robust sales contribution across operating segments drove Illumina's (ILMN) Q2 top line.